|
|
|
|
| LEADER |
03153nam a22003373i 4500 |
| 001 |
EBC30607168 |
| 003 |
MiAaPQ |
| 005 |
20231204023231.0 |
| 006 |
m o d | |
| 007 |
cr cnu|||||||| |
| 008 |
231204s2023 xx o ||||0 eng d |
| 020 |
|
|
|a 9789240074569
|q (electronic bk.)
|
| 035 |
|
|
|a (MiAaPQ)EBC30607168
|
| 035 |
|
|
|a (Au-PeEL)EBL30607168
|
| 035 |
|
|
|a (OCoLC)1402186796
|
| 040 |
|
|
|a MiAaPQ
|b eng
|e rda
|e pn
|c MiAaPQ
|d MiAaPQ
|
| 245 |
1 |
0 |
|a Target Product Profiles for Animal Plasma-Derived Antivenoms :
|b Antivenoms for Treatment of Snakebite Envenoming in Sub-Saharan Africa.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a Geneva :
|b World Health Organization,
|c 2023.
|
| 264 |
|
4 |
|c ©2023.
|
| 300 |
|
|
|a 1 online resource (45 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Cover -- Title -- Copyright -- Contents -- Acknowledgements -- Glossary of key terms and abbreviations -- Executive summary -- Introduction -- Unmet medical need/problem -- Rationale -- Use-case scenarios -- Scope of TPPs -- Indications and contraindications -- Manufacturing considerations -- Active pharmaceutical ingredient -- Finished product form -- Protein and immunoglobulin content -- Preclinical efficacy studies -- Clinical considerations -- Frequency and route of administration -- Stability, storage, presentation and packaging -- Affordability and access -- Supportive/adjunctive therapy -- Training and education -- Animal plasma-derived antivenom TPP list -- Target product profiles for sub-Saharan Africa -- Common characteristics of TPPs -- All sub-Saharan African, animal plasma-derived antivenoms -- Scope -- Manufacturing Consideraton -- Performance -- Operational Characteristics -- Specific characteristics of TPPs -- Broad-spectrum pan-African polyvalent antivenoms -- Scope -- Manufacturing Considerations -- Performance -- Sub-Saharan African monovalent antivenoms -- Scope -- Manufacturing Considerations -- Performance -- Pan-African polyvalent antivenoms for neurotoxic envenoming -- Scope -- Manufacturing Considerations -- Performance -- Pan-African polyvalent antivenoms for non-neurotoxic envenoming -- Scope -- Manufaturing Considerations -- Performance -- Clinical effectiveness of antivenoms for sub‑Saharan Africa -- Clinical Outcomes -- Death -- Restoration of blood coagulability -- Neurotoxicity -- Amputation and other functional loss -- Tissue necrosis -- Rhabdomyolysis -- Cost-effectiveness of antivenoms for sub-Saharan Africa -- References -- Bibliography.
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
|
| 655 |
|
4 |
|a Electronic books.
|
| 776 |
0 |
8 |
|i Print version:
|t Target Product Profiles for Animal Plasma-Derived Antivenoms
|d Geneva : World Health Organization,c2023
|
| 797 |
2 |
|
|a ProQuest (Firm)
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/matrademy/detail.action?docID=30607168
|z Click to View
|
